327.     S. García-Alonso, P. Mesa, L. de la Puente Ovejero1, G. Aizpurua, C.G. Lechuga1, E. Zarzuela, C.M. Santiveri, M. Sanclemente, J. Muñoz, M. Musteanu6, R. Campos-Oliva, J. Martínez-Torrecuadrada, M. Barbacid* and G. Montoya* (2022). Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation. Molecular Cell, 82:3438-3452. doi: 10.1016/j.molcel.2022.08.012. *Co-corresponding authors.

326.     L. Diego-González, A. Fernández-Carrera, A. Igea, A. Martínez-Pérez, M. C. D. Real Oliveira, A. C. Gomes, C. Guerra, M. Barbacid, A. González-Fernández and R. Simón-Vázquez (2022). Combined inhibition of FOSL-1 and YAP using siRNA-lipoplexes reduces the growth of pancreatic tumors. Cancers, 14:3102-3123. doi: 10.3390/cancers14133102.

325.     G. Paniagua, H.K.C. Jacob, O. Brehey, S. García-Alonso¹, C.G. Lechuga, T. Pons, M. Musteanu, C. Guerra, M. Drosten, and M. Barbacid (2022). KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Mol. Oncology, 16:3066-3081. doi: 10.1002/1878-0261.13213.

324.     M. Drosten and M. Barbacid (2022). Targeting KRAS Mutant lung cancer: Lung at the end of the tunnel. Mol. Oncology, 16:1057-1071. doi: 10.1002/1878-0261.13168.

323.     S. Rosigkeit, M. Kruchem, D. Thies, A. Kreft, E. Eichler, S. Boegel, S., Sandrine, D. Siegl, L. Kaps, G. Pickert, P. Haehnel, T. Kindler, U. Hartwig, C. Guerra, M. Barbacid, D. Schuppan and E. Bockamp (2021). Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer. Int Journal of Cancer, 49:1670-1682. doi: 10.1002/ijc.33756.

322.     M. Salmón, G. Paniagua, Carmen G. Lechuga, F. Fernández-García, E. Zarzuela, R. Álvarez-Díaz, M. Musteanu, C. Guerra, E. Caleiras, J. Muñoz, S. Ortega, M. Drosten and M. Barbacid (2021). KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proc. Natl. Acad. Sci. U.S.A., 118(30):e2023112118. doi: 10.1073

 321.     M. Assi, Y. Achouri, N. Dauguet, J. Baldan, C. Guerra, L. Bouwens, M. Barbacid, F. Lemaigre and P. Jacquemin (2021). Dynamic regulation of the expression of KRAS and its effectors determines the ability of pancreatic acinar cells to initiate tumorigenesis. Cancer Research, 81:2679-2689

320.     M. Sanclemente, P. Nieto, S. Garcia-Alonso, F. Fernández-García, L. Esteban-Burgo, C. Guerra, M. Drosten, E. Caleiras, J. Martinez-Torrecuadrada, D. Santamaría, M. Musteanu and M. Barbacid (2021) RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. Cancer Cell, 39:294-296.

This article was recommended in Faculty Opinions as being of special significance in its field

319.     C.G. Lechuga, M. Salmón, G. Paniagua, C. Guerra, M. Barbacid and M. Drosten (2021) RASless MEFs as a tool to study RAS-dependent and -independent functions. Methods Mol Biol., 2262:335-346

318.     L. Esteban-Burgos, H. Wang, P. Nieto, Jie Zheng, C. Blanco-Aparicio, C. Varela, G. Gómez-López, F. Fernández-García, M. Sanclemente, J. Galán, E. Caleiras, J. Martínez-Torrecuadrada, L. Fajas, S.B. Peng, D. Santamaría, M. Musteanu and M. Barbacid (2020) Tumor regression and Resistance Mechanisms upon CDK4 and RAF1 Inactivation in KRAS/p53 mutant lung adenocarcinomas. Proc. Natl. Acad. Sci. U.S.A., 117:24415-24426.

317.     E. Darbo, C. Travert, B. Drogat, A. Lacouture, S. San José, N. Cabrera, B. Turcq, V. Prouzet-Mauleon, M. Falcone, A. Villanueva, H. Wang, M. Herfs, M. Mosteiro, P. Jänne, J.L. Pujol, A. Maraver, M. Barbacid, E. Nadal, D. Santamaría and C. Ambrogio (2020). Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. JCI Insight, 2020;5(15):e137869.

316.     M. Drosten and M. Barbacid (2020) Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell, 37:543-550.

315.     J. Vitos-Faleato, A. Villanueva, M. Drosten, M. Barbacid and A.R. Nebreda (2020) Requirement for epithelial p38a in KRAS-driven lung tumor progression. Proc. Natl. Acad. Sci. U.S.A., 117:2588-2596.

314.     L. García-Gutiérrez, G. Bretones, E. Molin, I. Arechag, C. Symonds, J.C. Acosta, R. Blanco, A. Fernandez, L. Alonso, P. Sicinski, M. Barbacid, D. Santamaría and J. León. (2019). Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Sci Reports, 9:18693.doi:10.1038/s41598-019-54917-1.

313.     M. Barbacid. (2019). On the right TRK: from oncogene discovery to cancer therapeutics. Annals of Oncology, Suppl. 8: viii3-viii4.

312.     M.T. Blasco, C. Navas_, G. Martín-Serrano, O. Graña-Castro, C.G. Lechuga, L. Martín-Díaz, M. Djurec, J. Li, L. Morales-Cacho, L. Esteban-Burgos, J. Perales-Patón, E. Bousquet-Mur, E. Castellano, H.K.C. Jacob, L. Cabras, M Musteanu, M. Drosten, S. Ortega, F. Mulero, B. Sainz Jr., N. Dusetti, J. Iovanna, F. Sánchez-Bueno, M. Hidalgo, H. Khiabanian, R. Rabadán, F. Al-Shahrour, C. Guerra and M. Barbacid. (2019). Complete regression of advanced Pancreatic Ductal Adenocarcinomas upon combined inhibition of EGFR and c-RAF. Cancer Cell, 35:573-587.

Commentaries for this article appeared in:

Cancer Discovery, 9: 623 (2019)

Science Translational Medicine: J. Montero. Dual oncogene excision is greater than the sum of its parts. Vol 11, eaax4876 (2019).

311.      Z. Yao, Y. Gao, W. Su, R. Yaeger, J. Tao, N. Na, Y. Zhang, C. Zhang, A. Rymar, A. Tao, N.M.Timaul, R. Mcgriskin, N.A. Outmezguine, H.Y. Zhao, Q. Chang , B. Qeriqi, M. Barbacid, E. de Stanchina, D.M. Hyman, G. Bollag and N. Rosen. (2019).  PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nat. Medicine, 25:284-291.

310. M. Barbacid. (2018). How we isolated the TRK oncogene. The Cancer Letter, 44:9-10

309.     R. Sonntag, N. Giebeler, Y.A. Nevzorova, J.M. Bangen, D. Fahrenkamp D, Lambertz, U. Haas, W. Hu, N. Gassler, F.J.  Cubero, G. Müller-Newen, A.T. Abdallah, R. Weiskirchen, F. Ticconi, I.G. Costa, M. Barbacid, C. Trautwein and C. Liedtke. (2018). Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proc Natl Acad Sci U S A., 115:9282-9287.

308.     L. Cussó, M. Musteanu, F. Mulero, M. Barbacid and M. Desco (2018) Effects of a ketogenic diet on 18F-FDG-PET imaging in a mouse model of lung cancer. Mol. Imaging .Biol., 21:279-285

307.     H.P. Moll, K. Pranz, M. Musteanu, B. Grabner, N. Hruschka, J. Mohrherr, P. Aigner, P. Stiedl, L. Brcic, V. Laszlo, D. Schramek, R. Moriggl, R. Eferl, J. Moldvay, K. Dezso, P. P. Lopez-Casas3, D. Stoiber, M. Hidalgo, J. Penninger, M. Sibilia, B. Győrffy, M. Barbacid, B. Dome, H. Popper, E. Casanova. (2018). Afatinib restrains K-RAS driven lung tumorigenesis. Sci. Transl. Med., Jun 20;10(446):eaao2301. doi: 10.1126/scitranslmed.aao2301. PMID: 29925635

306.     C. Mayor-Ruiz, T. Olbrich, M. Drosten, E. Lecona, M. Vega-Sendino, S Ortega, O Dominguez, M. Barbacid, S. Ruiz and O. Fernandez-Capetillo. (2018). ERF deletion rescues RAS deficiency in mouse embryonic stem cells. Genes & Dev., 32:568-576.

305.     L. Simón-Carrasco, G. Jiménez, M. Barbacid and M. Drosten. (2018). The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle, 17:702-711.

304.     Y. Gao, M. Chang, D. McKay, N. Na, B. Zhou, R. Yaeger, N. Torres, K. Muniz, M. Drosten, M. Barbacid, G. Caponigro, D. Stuart, H. Möbitz, D. Solit, O. Abdel-Wahab, B. Taylor, Z. Yao, and N. Rosen. (2018) Allele-specific mechanisms of activation of MEK1 mutants determine their properties. Cancer Discovery, 8:648-661.

303.     M. Djurec, O. Graña, A. Lee, K. Troulé, E. Espinet, L. Cabras, C. Navas_, M.T. Blasco, L. Martín-Díaz, M. Burdiel, J. Li, Z. Liu, M. Vallespinós, F. Sanchez-Bueno, M.R. Sprick, A. Trumpp⁴, B. Sainz Jr, F. Al-Shahrour, R. Rabadán, C. Guerra and M. Barbacid. (2018). Saa3 is a key mediator of the pro-tumorigenic properties of cancer associated fibroblasts in pancreatic tumors. Proc. Natl. Acad. Sci. U.S.A., 115:E1147-E1156.

302.     M. Sanclemente, S. Francoz, L. Esteban-Burgos, E. Bousquet-Mur, M. Djurec, PP. Lopez-Casas, M. Hidalgo, C. Guerra, M. Drosten, M. Musteanu and M. Barbacid.^. (2018) c-Raf Ablation Induces Regression of Advanced K-Ras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell, 33: 217-228.

Commentaries for this article appeared in:

Cancer Cell: F. McCormick: c-Raf in KRas Mutant Cancers: A Moving Target. Cancer Cell, 33: 158-159

Science Translational Medicine: A. Lujambio A new hope for KRAS mutant cancers. Sci Transl. Medicine, 10: eaas8964  http://stm.sciencemag.org/content/10/429/eaas8964.full

This article was also recommended in F1000Prime as being of special significance in its field